Intratumoral Alpha-Emitter Radiation and Activation of Cytoplasmatic Sensors for Intracellular Pathogen
AssigneeAlpha Tau Medical Ltd.
InventorsVered Domankevich, Yona Keisari, Itzhak Kelson
Life of this patent
Estimating the term…
Abstract
A method of treating a patient with a tumor, comprising administering, to the patient, a substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor, in one or more doses; and treating the tumor with intra-tumoral alpha-emitter radiotherapy within two weeks of administering the substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor, and at least 12 hours after administering the substance. The substance is selected from the group of a DNA methyltransferase (DNMT) inhibitor, and a histone deacetylase (HDAC) inhibitor.
Claims17
A method of treating a patient with a tumor, comprising:
- administering, to the patient, a substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor, in one or more doses;
- and
- treating the tumor with intra-tumoral alpha-emitter radiotherapy within two weeks of administering the substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor, and at least 12 hours after administering the substance,
- wherein the substance is selected from the group of:
- a DNA methyltransferase (DNMT) inhibitor, and
- a histone deacetylase (HDAC) inhibitor.
Dependencies are inferred from the claim text.